Benzinga · Aug 26, 2026
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.
SK
NASDAQ · SKYE
Skye Bioscience, Inc.
Healthcare · Biotechnology
$2.04
Down-$0.04 (-1.92%)
Updated Sep 12, 2026, 9:20 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.01M
- P/E ratio
- -1.08
- Dividend yield
- 0.00%
- 52-week range
- $0.28 – $3.56
- Volume
- 66.18K
- Avg. volume
- 819.32K
Price performance
SKYE price history
1M range · 20 trading sessions · Daily adjusted prices
SKYE closed at $2.04 after 20 trading sessions, up 306.78% for the selected period.
- Last close
- $2.04
- Period change
- +306.78%
- Period low
- $0.42
- Period high
- $2.87
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.08 | $2.09 | $1.99 | $2.04 | 66.18K |
| Sep 10, 2026 | $2.20 | $2.2399 | $2.02 | $2.08 | 47.79K |
| Sep 9, 2026 | $1.88 | $2.25 | $1.88 | $2.23 | 172.31K |
| Sep 8, 2026 | $1.97 | $1.97 | $1.80 | $1.88 | 106.51K |
| Sep 4, 2026 | $1.77 | $1.95 | $1.77 | $1.86 | 183.11K |
| Sep 3, 2026 | $1.84 | $1.89 | $1.77 | $1.78 | 22.25K |
| Sep 2, 2026 | $1.79 | $2.05 | $1.76 | $1.84 | 134.64K |
| Sep 1, 2026 | $1.69 | $1.81 | $1.64 | $1.80 | 51.91K |
| Aug 31, 2026 | $1.75 | $1.80 | $1.665 | $1.68 | 70.74K |
| Aug 28, 2026 | $1.95 | $1.95 | $1.76 | $1.775 | 78.29K |
| Aug 27, 2026 | $2.00 | $2.02 | $1.95 | $1.95 | 52.98K |
| Aug 26, 2026 | $2.02 | $2.05 | $1.8429 | $2.02 | 111.35K |
| Aug 25, 2026 | $2.10 | $2.155 | $2.0003 | $2.015 | 65.26K |
| Aug 24, 2026 | $2.26 | $2.32 | $1.97 | $2.17 | 162.27K |
| Aug 21, 2026 | $2.2432 | $2.272 | $2.04 | $2.24 | 121.82K |
| Aug 20, 2026 | $2.424 | $2.60 | $2.208 | $2.2432 | 199.78K |
| Aug 19, 2026 | $2.728 | $3.0216 | $2.40 | $2.4472 | 173.46K |
| Aug 18, 2026 | $3.0776 | $3.5616 | $2.80 | $2.872 | 227.83K |
| Aug 17, 2026 | $0.5703 | $0.5857 | $0.4128 | $0.4151 | 9.44M |
| Aug 14, 2026 | $0.86 | $0.88 | $0.4732 | $0.5015 | 6.6M |
Latest SKYE news
The latest Smart Investors Daily articles mentioning SKYE.
Stock researchCompany · Overview
SKYE research
Overview
Company profile and research snapshot.
Company profile
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | Evercore ISI Group | Outperform | — |
| Jun 24, 2025 | JMP Securities | Market Outperform | — |
| Mar 21, 2025 | Citizens Capital Markets | Market Outperform | — |
| Mar 21, 2025 | Craig-Hallum | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M
Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the "Company"), with the U.S. Securities and Exchange
SeekingAlpha · Aug 16, 2026
Skye Bioscience, Inc. (SKYE) Skye Bioscience, Inc. - M&A Call - Slideshow
SeekingAlpha · Aug 14, 2026
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Skye Bioscience, Inc. (SKYE) M&A Call August 14, 2026 10:00 AM EDTCompany ParticipantsPunit Dhillon - President, CEO & DirectorLisa Mary Anson - CEO...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
